Ingenol Mebutate Gel, 0.015%

DRUG3 trials

Sponsors

LEO Pharma

Conditions

Actinic KeratosisActinic Keratosis (AK)

Phase 3

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

CompletedNCT01600014

LEO PharmaActinic Keratosis

Start: 2012-05-31End: 2014-02-28Updated: 2025-03-10

Phase 4

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

CompletedNCT01926496

LEO PharmaActinic Keratosis (AK)

Start: 2013-09-11End: 2019-07-11Updated: 2025-03-07

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

CompletedNCT02406014

LEO PharmaActinic Keratosis (AK)

Start: 2015-04-30End: 2016-06-30Updated: 2025-02-24

Related Papers

5PSQ-136 Disproportionality analysis of the skin toxicity of ingenol mebutate using the FDA Adverse Event Reporting System database

Section 5: Patient safety and quality assurance2021-03-01

Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.

2018-01-1520 citations